{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T02:31:24Z","timestamp":1787452284649,"version":"build-2736575974"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2024ZD0537707"],"award-info":[{"award-number":["2024ZD0537707"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82030007"],"award-info":[{"award-number":["82030007"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U23A20398"],"award-info":[{"award-number":["U23A20398"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.metabol.2025.156433","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T10:24:48Z","timestamp":1762597488000},"page":"156433","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["GLP-1RAs and tirzepatide may reduce heart failure risk in obese but not in non-obese patients with cardiovascular or renal disease: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"175","author":[{"given":"Ju","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangfeng","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mowei","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.metabol.2025.156433_bb0005","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"issue":"9889","key":"10.1016\/j.metabol.2025.156433_bb0010","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.metabol.2025.156433_bb0015","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/ki.2011.379","article-title":"Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis","volume":"81","author":"Coca","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.metabol.2025.156433_bb0020","article-title":"Global trends and disparities in the burden of heart failure caused by chronic kidney disease: an analysis of the global burden of disease study 2021","volume":"12","author":"Ye","year":"2025","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"10.1016\/j.metabol.2025.156433_bb0025","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nrendo.2017.151","article-title":"Global aetiology and epidemiology of type 2 diabetes mellitus and its complications","volume":"14","author":"Zheng","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.metabol.2025.156433_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.118585","article-title":"Association between different stages of cardiovascular-kidney-metabolic syndrome and the risk of all-cause mortality","volume":"397","author":"Li","year":"2024","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.metabol.2025.156433_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24087184","article-title":"The effects of cardioprotective antidiabetic therapy on microbiota in patients with type 2 diabetes mellitus-a systematic review","volume":"24","author":"Bica","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"13","key":"10.1016\/j.metabol.2025.156433_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310449","article-title":"Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials","volume":"24","author":"Popoviciu","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.metabol.2025.156433_bb0045","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.metabol.2025.156433_bb0050","article-title":"GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs","volume":"20","author":"Giugliano","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"10.1016\/j.metabol.2025.156433_bb0055","article-title":"Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes","volume":"2","author":"Natale","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.metabol.2025.156433_bb0060","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.cardfail.2025.01.022","article-title":"Efficacy of GLP-1 receptor agonists in patients with heart failure and mildly reduced or preserved ejection fraction: a systematic review and Meta-analysis","volume":"31","author":"Waqas","year":"2025","journal-title":"J Card Fail"},{"issue":"4","key":"10.1016\/j.metabol.2025.156433_bb0065","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like Peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2025.156433_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113517","article-title":"Glucose control independent mechanisms involved in the cardiovascular benefits of glucagon-like peptide-1 receptor agonists","volume":"153","author":"Wu","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.metabol.2025.156433_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156038","article-title":"Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials","volume":"161","author":"Xie","year":"2024","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.metabol.2025.156433_bb0080","doi-asserted-by":"crossref","first-page":"E24","DOI":"10.1152\/ajpendo.00179.2022","article-title":"Obesity and chronic kidney disease","volume":"324","author":"Jiang","year":"2023","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.metabol.2025.156433_bb0085","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13450","article-title":"Obesity-related glomerulopathy: current approaches and future perspectives","volume":"23","author":"Mart\u00ednez-Montoro","year":"2022","journal-title":"Obes Rev"},{"key":"10.1016\/j.metabol.2025.156433_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101799","article-title":"Oxidative stress and diabetic retinopathy: molecular mechanisms, pathogenetic role and therapeutic implications","volume":"37","author":"Kang","year":"2020","journal-title":"Redox Biol"},{"key":"10.1016\/j.metabol.2025.156433_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.103021","article-title":"GLP-1 receptor agonists beyond diabetes management","volume":"78","author":"eClinicalMedicine","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.metabol.2025.156433_bb0100","article-title":"Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists","volume":"15","author":"Liu","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"10.1016\/j.metabol.2025.156433_bb0105","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.30952","article-title":"GLP-1 RAs and cardiovascular and kidney outcomes by body mass index in type 2 diabetes","volume":"8","author":"Chen","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.metabol.2025.156433_bb0110","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2337\/dci23-0041","article-title":"Cardiovascular and kidney risks in individuals with type 2 diabetes: contemporary understanding with greater emphasis on excess adiposity","volume":"47","author":"Sattar","year":"2024","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.metabol.2025.156433_bb0115","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1007\/s00125-022-05731-4","article-title":"Precision prognostics for the development of complications in diabetes","volume":"65","author":"Schiborn","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2025.156433_bb0120","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.metabol.2025.156433_bb0125","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.metabol.2025.156433_bb0130","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jclinepi.2022.07.015","article-title":"GRADE guidance 35: update on rating imprecision for assessing contextualized certainty of evidence and making decisions","volume":"150","author":"Sch\u00fcnemann","year":"2022","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.metabol.2025.156433_bb0135","doi-asserted-by":"crossref","first-page":"204","DOI":"10.4103\/1027-8117.362992","article-title":"Tenessential steps for performing a systematic review: a quick tutorial","volume":"40","author":"Kuo","year":"2022","journal-title":"Dermatol Sin"},{"issue":"19","key":"10.1016\/j.metabol.2025.156433_bb0140","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.metabol.2025.156433_bb0145","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S2213-8587(19)30192-5","article-title":"Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1016\/j.metabol.2025.156433_bb0150","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.metabol.2025.156433_bb0155","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.metabol.2025.156433_bb0160","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.metabol.2025.156433_bb0165","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.metabol.2025.156433_bb0170","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of Semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.metabol.2025.156433_bb0175","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","volume":"392","author":"McGuire","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.metabol.2025.156433_bb0180","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.metabol.2025.156433_bb0185","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of Liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"316","author":"Margulies","year":"2016","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.metabol.2025.156433_bb0190","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2337\/dc14-2883","article-title":"Efficacy and safety of Liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial","volume":"39","author":"Davies","year":"2016","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.metabol.2025.156433_bb0195","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"10193","key":"10.1016\/j.metabol.2025.156433_bb0200","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.metabol.2025.156433_bb0205","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med"},{"issue":"10157","key":"10.1016\/j.metabol.2025.156433_bb0210","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.metabol.2025.156433_bb0215","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly Exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.metabol.2025.156433_bb0220","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41591-021-01584-3","article-title":"Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial","volume":"28","author":"Ruff","year":"2022","journal-title":"Nat Med"},{"issue":"23","key":"10.1016\/j.metabol.2025.156433_bb0225","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2025.156433_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156113","article-title":"Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: systematic review and network meta-analysis","volume":"164","author":"Karakasis","year":"2025","journal-title":"Metabolism"},{"issue":"10","key":"10.1016\/j.metabol.2025.156433_bb0235","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2025.156433_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2023.100502","article-title":"Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection","volume":"14","author":"Michos","year":"2023","journal-title":"Am J Prev Cardiol"},{"issue":"1","key":"10.1016\/j.metabol.2025.156433_bb0245","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2025.156433_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.111999","article-title":"Comparison of the effectiveness and safety of GLP-1 receptor agonists for type 2 diabetes mellitus patients with overweight\/obesity: a systematic review and network meta-analysis","volume":"222","author":"Wen","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"10.1016\/j.metabol.2025.156433_bb0255","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s10741-025-10523-0","article-title":"The effect of GLP-1 receptor agonists on cardiac remodeling in heart failure patients with preserved and reduced ejection fraction: a systematic review and meta-analysis","volume":"30","author":"Siddiqui","year":"2025","journal-title":"Heart Fail Rev"},{"issue":"2","key":"10.1016\/j.metabol.2025.156433_bb0260","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/ehjcvp\/pvae093","article-title":"Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in atherosclerotic cardiovascular disease phenotypes: a systematic review and meta-analysis","volume":"11","author":"Lin","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.metabol.2025.156433_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156043","article-title":"Comparative efficacy of THR-\u03b2 agonists, FGF-21 analogues, GLP-1R agonists, GLP-1-based polyagonists, and Pan-PPAR agonists for MASLD: a systematic review and network meta-analysis","volume":"161","author":"Lin","year":"2024","journal-title":"Metabolism"},{"issue":"24","key":"10.1016\/j.metabol.2025.156433_bb0270","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes","volume":"146","author":"Marx","year":"2022","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.metabol.2025.156433_bb0275","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.diabet.2012.04.003","article-title":"Harnessing the incretin system beyond glucose control: potential cardiovascular benefits of GLP-1 receptor agonists in type 2 diabetes","volume":"38","author":"Cariou","year":"2012","journal-title":"Diabetes Metab"},{"issue":"6","key":"10.1016\/j.metabol.2025.156433_bb0280","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1111\/dom.15529","article-title":"Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: a meta-analysis and meta-regression","volume":"26","author":"Rivera","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2025.156433_bb0285","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3094642","article-title":"Anti-inflammatory effects of GLP-1-based therapies beyond glucose control","volume":"2016","author":"Lee","year":"2016","journal-title":"Mediators Inflamm"},{"issue":"6","key":"10.1016\/j.metabol.2025.156433_bb0290","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1016\/j.apsb.2024.03.011","article-title":"Glucagon-like peptide-1 receptor agonists rescued diabetic vascular endothelial damage through suppression of aberrant STING signaling","volume":"14","author":"He","year":"2024","journal-title":"Acta Pharm Sin B"},{"issue":"3","key":"10.1016\/j.metabol.2025.156433_bb0295","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1007\/s12020-024-03757-9","article-title":"Renal effects of GLP-1 receptor agonists and tirzepatide in individuals with type 2 diabetes: seeds of a promising future","volume":"84","author":"Caruso","year":"2024","journal-title":"Endocrine"},{"issue":"10","key":"10.1016\/j.metabol.2025.156433_bb0300","doi-asserted-by":"crossref","DOI":"10.1111\/1753-0407.13609","article-title":"Glucagon-like peptide-1 receptor agonists and kidney outcomes","volume":"16","author":"MacIsaac","year":"2024","journal-title":"J Diabetes"},{"issue":"4","key":"10.1016\/j.metabol.2025.156433_bb0305","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1681\/ASN.2016060666","article-title":"Glomerular Hyperfiltration in diabetes: mechanisms, clinical significance, and treatment","volume":"28","author":"Tonneijck","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.metabol.2025.156433_bb0310","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-55724-z","article-title":"The impact of GLP-1 receptor agonist liraglutide on blood pressure profile, hydration, natriuresis in diabetic patients with severely impaired kidney function","volume":"14","author":"Wajdlich","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.metabol.2025.156433_bb0315","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s10741-024-10450-6","article-title":"GLP-1 receptor agonists as promising anti-inflammatory agents in heart failure with preserved ejection fraction","volume":"30","author":"Bonfioli","year":"2025","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.metabol.2025.156433_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"issue":"6","key":"10.1016\/j.metabol.2025.156433_bb0325","doi-asserted-by":"crossref","DOI":"10.3390\/ph16060836","article-title":"Multifaceted roles of GLP-1 and its analogs: a review on molecular mechanisms with a cardiotherapeutic perspective","volume":"16","author":"Pandey","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"10.1016\/j.metabol.2025.156433_bb0330","doi-asserted-by":"crossref","DOI":"10.1002\/jcsm.13677","article-title":"The effects of glucagon-like peptide-1 receptor agonists on mitochondrial function within skeletal muscle: a systematic review","volume":"16","author":"Old","year":"2025","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.metabol.2025.156433_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155664","article-title":"From non-alcoholic fatty liver disease (NAFLD) to steatotic liver disease (SLD): an ongoing journey towards refining the terminology for this prevalent metabolic condition and unmet clinical need","volume":"147","author":"Kokkorakis","year":"2023","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.metabol.2025.156433_bb0340","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"European Association for the Study of the Liver (EASL)","year":"2024","journal-title":"J Hepatol"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049525003026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049525003026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:21:01Z","timestamp":1781065261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049525003026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":68,"alternative-id":["S0026049525003026"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2025.156433","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1RAs and tirzepatide may reduce heart failure risk in obese but not in non-obese patients with cardiovascular or renal disease: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2025.156433","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156433"}}